MINI LONG - GILEAD SCIENCES | Delayed Börse Stuttgart 03:13:25 2024-06-27 EDT | ||
| 2.67 EUR | -1.11% |
|
| Current month | +27.36% | ||
| 1 month | +19.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 2.67 | -1.11% |
| 24-06-26 | 2.7 | -0.74% |
| 24-06-25 | 2.72 | -4.90% |
| 24-06-24 | 2.86 | +1.78% |
| 24-06-21 | 2.81 | +7.66% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 03:13 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Citi
|
| WKN | CF2N3N |
| ISIN | DE000CF2N3N9 |
| Date issued | 2013-06-07 |
| Strike | 40.65 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.17 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.55 € |
|---|---|
| Lowest since issue | 1.03 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.31
USD
Average target price
82.97
USD
Spread / Average Target
+19.70%
- Stock Market
- Certificates
- Certificat
